Arcutis Biotherapeutics
ARQT

$10.07

0.59%

Market Cap: 1.17B

About: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Employees: 296

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 8 analysts

0

News positive %

of 7 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

500% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 6 (+5) [Q1 2024]

278% more capital invested

Capital invested by funds: $327M [Q4 2023] → $1.24B (+$910M) [Q1 2024]

124% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 25

28% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 40

23% more funds holding

Funds holding: 132 [Q4 2023] → 163 (+31) [Q1 2024]

1.25% more ownership

Funds ownership: 107.29% [Q4 2023] → 108.54% (+1.25%) [Q1 2024]

42% less call options, than puts

Call options by funds: $6.39M | Put options by funds: $11.1M

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$11

9%

upside

Avg. target

$16.25

61%

upside

High target

$18

79%

upside

8 analyst ratings

7 positive

88%

1 neutral

13%

0 negative

0%

Needham Serge Belanger	79%upside $18	Buy Reiterated	10 Jul 2024
Needham Serge Belanger	79%upside $18	Buy Maintained	15 May 2024
Mizuho Uy Ear	79%upside $18	Buy Maintained	15 May 2024
Needham Serge Belanger	59%upside $16	Buy Reiterated	12 Apr 2024
Goldman Sachs Jonathan Block	9%upside $11	Neutral Maintained	28 Feb 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about ARQT published over the past 30 days

7 Biotech Stocks to Keep on Your Clinical Radar

Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.

7 Biotech Stocks to Keep on Your Clinical Radar

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

WESTLAKE VILLAGE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring a leading dermatology and immune-mediated skin disease expert to discuss the unmet need and current treatment landscape for individuals with mild to moderate atopic dermatitis (AD).

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

Zacks Investment Research

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration AD is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States Third FDA approval for Company in two years Commercial product expected to be available by the end of July WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

The 7 Best Under $10 Stocks to Buy in July 2024

Savvy investors are discovering rewarding opportunities in some of the best stocks under $10 a share. Years ago, I found Advanced Micro Devices (NASDAQ: AMD ) at $10 a share and watched it rocket above $200 on the artificial intelligence (AI) boom.

The 7 Best Under $10 Stocks to Buy in July 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 325,000 restricted stock units of Arcutis' common stock as well as options to purchase an aggregate of 55,000 shares of Arcutis' common stock to 43 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors Business Daily

Cheap Stocks To Buy: Is It Time To Buy This Ship Transport Leader?

Banco BBVA has now made two tests of this key technical level in nearly three weeks.

Cheap Stocks To Buy: Is It Time To Buy This Ship Transport Leader?

Zacks Investment Research

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

Zacks Investment Research

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

See News Rankings